US FDA gives NuPathe's migraine patch 2nd look; verdict set for January
This article was originally published in Scrip
Executive Summary
The US FDA has accepted for review NuPathe's resubmitted new drug application for its transdermal sumatriptan migraine patch NP101, giving the firm's shares a 3.6% boost on 31 July, before closing at $3.91, or a gain of 4 cents.